UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms

 
• By John Davis
  
Acceleration
The development of rozanolixizumab is to be accelerated. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category